However, the management and treatment of MS has become more complex over the last two decades and after the approval of interferon beta-1b (IFNβ) as the first disease-modifying drug (DMD), many medication have been available for the treatment of MS, with different mechanisms of action, and different effectiveness and safety profiles [69]. The gene discussed is IFNB1; the disease is myeloid sarcoma.